Cargando…
Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy
In oral and maxillofacial surgery, flap repair is essential to the quality of postoperative life. Still, thrombosis is fatal for the survival of the flaps. Besides, some postoperative thrombotic diseases, such as pulmonary embolism, also intimidate patients’ life. The traditional diagnostic methods...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563174/ https://www.ncbi.nlm.nih.gov/pubmed/36242039 http://dx.doi.org/10.1186/s12951-022-01649-6 |
_version_ | 1784808339260047360 |
---|---|
author | Cao, Zichen Zhang, Xinyu Wei, Zheng Song, Chuanhui Zou, Huihui Ran, Jianchuan Zhang, Hongbo Xie, Diya Han, Shengwei Wang, Yufeng Cai, Yu Han, Wei |
author_facet | Cao, Zichen Zhang, Xinyu Wei, Zheng Song, Chuanhui Zou, Huihui Ran, Jianchuan Zhang, Hongbo Xie, Diya Han, Shengwei Wang, Yufeng Cai, Yu Han, Wei |
author_sort | Cao, Zichen |
collection | PubMed |
description | In oral and maxillofacial surgery, flap repair is essential to the quality of postoperative life. Still, thrombosis is fatal for the survival of the flaps. Besides, some postoperative thrombotic diseases, such as pulmonary embolism, also intimidate patients’ life. The traditional diagnostic methods are still limited by a large amount of hardware and suffer from inconvenience, delay, and subjectivity. Moreover, the treatments mainly rely upon thrombolytics, such as urokinase (UK) plasminogen activator, which may cause bleeding risk, especially intracerebral hemorrhage. Herein, a kind of poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing a first near-infrared window (NIR-I) phototheranostic agent Y8 and urokinase plasminogen activator (UK) as the core, and modified with the fibrin-targeting peptide Gly–Pro–Arg–Pro–Pro (GPRPP) were developed for the flap and postoperative thromboembolism treatment (named GPRPP-Y8U@P). The conjugated molecule Y8 endows GPRPP-Y8U@P with the capacity of NIR-II imaging and excellent photothermal/photodynamic therapeutic effects. In vivo experiments demonstrated that GPRPP-Y8U@P could quickly locate thrombus by NIR-II fluorescence imaging, and semi-quantitative analysis of the embolized blood vessels' paraffin section verified its thrombolytic efficiency. Additionally, the urokinase trapped in the NPs would not result in nonspecific bleeding, tremendously improving physical security and curative effects with minimizing side effects. Overall, the advantages of GPRPP-Y8U@P, such as precise localization of the thrombus, thrombus ablation in the site, and mild side effects, demonstrated the attractiveness of this approach for effective clinical monitoring of thrombus therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01649-6. |
format | Online Article Text |
id | pubmed-9563174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95631742022-10-15 Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy Cao, Zichen Zhang, Xinyu Wei, Zheng Song, Chuanhui Zou, Huihui Ran, Jianchuan Zhang, Hongbo Xie, Diya Han, Shengwei Wang, Yufeng Cai, Yu Han, Wei J Nanobiotechnology Research In oral and maxillofacial surgery, flap repair is essential to the quality of postoperative life. Still, thrombosis is fatal for the survival of the flaps. Besides, some postoperative thrombotic diseases, such as pulmonary embolism, also intimidate patients’ life. The traditional diagnostic methods are still limited by a large amount of hardware and suffer from inconvenience, delay, and subjectivity. Moreover, the treatments mainly rely upon thrombolytics, such as urokinase (UK) plasminogen activator, which may cause bleeding risk, especially intracerebral hemorrhage. Herein, a kind of poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing a first near-infrared window (NIR-I) phototheranostic agent Y8 and urokinase plasminogen activator (UK) as the core, and modified with the fibrin-targeting peptide Gly–Pro–Arg–Pro–Pro (GPRPP) were developed for the flap and postoperative thromboembolism treatment (named GPRPP-Y8U@P). The conjugated molecule Y8 endows GPRPP-Y8U@P with the capacity of NIR-II imaging and excellent photothermal/photodynamic therapeutic effects. In vivo experiments demonstrated that GPRPP-Y8U@P could quickly locate thrombus by NIR-II fluorescence imaging, and semi-quantitative analysis of the embolized blood vessels' paraffin section verified its thrombolytic efficiency. Additionally, the urokinase trapped in the NPs would not result in nonspecific bleeding, tremendously improving physical security and curative effects with minimizing side effects. Overall, the advantages of GPRPP-Y8U@P, such as precise localization of the thrombus, thrombus ablation in the site, and mild side effects, demonstrated the attractiveness of this approach for effective clinical monitoring of thrombus therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01649-6. BioMed Central 2022-10-14 /pmc/articles/PMC9563174/ /pubmed/36242039 http://dx.doi.org/10.1186/s12951-022-01649-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cao, Zichen Zhang, Xinyu Wei, Zheng Song, Chuanhui Zou, Huihui Ran, Jianchuan Zhang, Hongbo Xie, Diya Han, Shengwei Wang, Yufeng Cai, Yu Han, Wei Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
title | Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
title_full | Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
title_fullStr | Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
title_full_unstemmed | Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
title_short | Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
title_sort | thrombus-targeted nano-agents for nir-ii diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563174/ https://www.ncbi.nlm.nih.gov/pubmed/36242039 http://dx.doi.org/10.1186/s12951-022-01649-6 |
work_keys_str_mv | AT caozichen thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT zhangxinyu thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT weizheng thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT songchuanhui thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT zouhuihui thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT ranjianchuan thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT zhanghongbo thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT xiediya thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT hanshengwei thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT wangyufeng thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT caiyu thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy AT hanwei thrombustargetednanoagentsforniriidiagnosticfluorescenceimagingguidedflapthromboembolismmultimodeltherapy |